Invention Grant
- Patent Title: Treatment of bleeding with low half-life fibrinogen
-
Application No.: US14933532Application Date: 2015-11-05
-
Publication No.: US09962431B2Publication Date: 2018-05-08
- Inventor: Frank Pieper , Anurag Relan , Erik Jordahl Forsberg
- Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
- Applicant Address: FR Les Ulis
- Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
- Current Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
- Current Assignee Address: FR Les Ulis
- Agency: Potomac Law Group, PLLC
- Main IPC: A61K38/36
- IPC: A61K38/36 ; A61K38/37 ; C07K14/75
Abstract:
A pharmaceutical composition of recombinant human fibrinogen having a half-life of less than 12 hours and a pharmaceutically acceptable carrier or diluent. The pharmaceutical composition may also contain factor VIIa, factor VIII, von Willebrand's factor, or Desmopressin. The pharmaceutical composition may also contain divalent metal cations. The recombinant human fibrinogen may contain sialic acid.
Public/Granted literature
- US20160106815A1 TREATMENT OF BLEEDING WITH LOW HALF-LIFE FIBRINOGEN Public/Granted day:2016-04-21
Information query
IPC分类:
